A Three-Arm, Observational, Pilot Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure
The purpose of this study is to assess the performance of 68Ga- FAPI PET in heart failure with preserved ejection fraction (HFpEF)
• Patients aged ≥ 30 years old with exertional dyspnea (NYHA II and III) and LVEF ≥50%
• BMI ≥ 30
• New diagnosis of HFpEF based on RHC at baseline (elevated PCWP at rest and/or during exercise)
• Ambulatory patients aged ≥ 18 years old
• New referrals to the Sarcoid Clinic with a confirmed but untreated diagnosis of definite or probable CS based on 2014 HRS consensus (see Table 2)
• With a positive cardiac 18F-FDG PET scan within 30 days.
• Adults ≥ 30 years old
• No major chronic disease (cardiopulmonary, inflammatory, autoimmune, cancer, renal or liver impairment, etc.)
• No intake of relevant medication, defined as regular intake of at least one of the following: anticoagulants, antiplatelets, antihypertensive / diuretics, antidiabetics, antiarrhythmic, immunosuppressants, chemotherapy, antibiotics/antivirals/antifungals